Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a fecal transplant beat a stubborn stomach bug?

NCT ID NCT07704255

Disease control Sponsor: Sichuan Provincial People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests whether transplanting healthy gut bacteria from a donor can help clear a hard-to-treat H. pylori infection. Adults aged 18 to 70 who have failed at least four standard treatments will receive a fecal microbiota transplant through the anus. The goal is to see if this approach can successfully eradicate the bacteria, offering an alternative for those with resistant infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fecal microbiota transplant given through the anus
What this could lead to
If it works, this could offer a new way to treat hard-to-clear H. pylori infections without relying on more antibiotics.
What could go wrong
This is a very small early-phase trial with only 10 participants, so results may not apply widely. The procedure carries risks of infection or other complications from the transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Ages 18-70 * 2\. Hp infection treatment failed ≥4 times with guidelines-recommended therapies * 3\. Patients with early gastric cancer, peptic ulcer, gastric MALT lymphoma, atrophic gastritis and other diseases requiring the eradication of Hp. Exclusion Criteria: * 1\. Antibiotics and bismuth were taken within 4 weeks before this treatment; Or had taken PPI, H2 receptor antagonist, P-CAB within 2 weeks prior to treatment; * 2\. Pregnant or lactating women; * 3\. Those who are allergic to the investigational drugs used in this test or have contraindications; * 4\. Participated in other drug trials within 3 months before the treatment of this trial; * 5\. There are other serious diseases that affect the evaluation of this study at the same time, or they cannot correctly express their own complaints and cannot cooperate; * 6\. Subjects with dysphagia; * 7\. Patients with malignant tumors, serious concomitant diseases, severe ulcer bleeding or perforation; * 8\. Patients judged by the investigator to be unsuitable for clinical trials. * 9\. Those who do not want to sign the informed consent for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Helicobacter pylori infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Helicobacter pylori infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, Sichuan, 601172, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.